
- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com

As drug development programs become more complex, customers need partners that understand their needs, build capabilities ahead of demand and have capacity available as programs advance. WuXi AppTec continues to evolve its Contract Research, Development and Manufacturing Organization (CRDMO) model to connect research, development, and manufacturing around those needs. Dr. Steve Yang, Co-CEO of WuXi AppTec, discussed this approach at BIO-Europe 2026, held in Cologne, Germany, in November.
Drug discovery and development inherently involve scientific uncertainty, but today’s capital markets and supply chain pressures create additional complexity. Regardless, innovators around the world still need to turn scientific concepts into tangible therapies.
Dr. Yang explained how WuXi AppTec adapts its approach to these evolving needs to better support customers.
“For large pharmaceutical companies, we seek to build long-term collaborations under a rigorous framework that allows multiple projects to move forward in parallel. For biotechs, we stay agile and flexible, helping them initiate projects quickly,” Dr. Yang said.
Guided by this philosophy of collaboration, WuXi AppTec has worked with many large pharmaceutical companies for more than 20 years. Relationships that began in early-stage research chemistry have expanded across chemistry, biology and testing, and into development and manufacturing. The modalities the company supports have also expanded to include peptides, oligonucleotides, and complex conjugates alongside traditional small molecules.
Dr. Yang pointed to continued business growth as a key indication of customers’ trust in the company.
“We will continue to focus on what we do, consistently playing the role of an innovation enabler and helping accelerate global innovation,” he said.
As new modalities and new therapies emerge, drug discovery and development are becoming more complex. This requires innovators to deepen collaboration with external partners.
Dr. Yang described increasing complexity in the molecules WuXi AppTec synthesizes for customers. WuXi AppTec synthesized and delivered more than 450,000 new compounds for customers over the last 12 months. Over the past five years, average molecular weight has increased by 30%. The proportion of molecules above 600 daltons has surged by 141%, while molecules requiring lengthy synthetic routes now involve 22% more steps on average.
“All of this indicates a common trend regardless of uncertainty. That is, the innovators, whether they be biotech or large pharma, need new solutions and technologies to make those molecules and take them to patients…To me, that's the certainty in the midst of uncertainties.” Dr. Yang observed.
WuXi AppTec has been able to meet customers’ needs because the company’s approach is to “follow the science.”
“Today’s niche demand may become tomorrow’s common need,” Dr. Yang said.
Peptides offer an example of how this approach works. In 2018, WuXi AppTec began building capabilities spanning peptide discovery, development, and manufacturing to anticipate customers’ needs.
Dr. Yang said WuXi AppTec currently supports 29 GLP-1 drug programs at clinical or commercial stages. The company also supports work on protein degraders, oligonucleotides, and a range of conjugated molecules.
Working with thousands of customers provides WuXi AppTec with insight into emerging needs. When multiple customers request similar capabilities, the company considers developing them into shared platforms. This can make specialized expertise and technologies available to companies that would otherwise need to build them, helping clients reduce cost and improve efficiency, creating value across the innovation ecosystem and bringing hope to more patients.

Global biopharma continues to show strong demand for critical capacity and capability, and where work takes place matters to customers. Customer needs continue to drive WuXi AppTec’s investment across Europe, North America, and Asia to optimize its global operating network, Dr. Yang said.
In Switzerland, WuXi AppTec announced the opening of its commercial-scale spray-drying facility at Couvet in October 2026. In Germany, the company relocated its Munich laboratories and offices to a new facility and is continuing to invest in the site.
In the United States, the Middletown facility in Delaware is set to enter full operation as the company’s first large-scale formulation manufacturing site in the country. The company expects Phase I of its Singapore site to begin operations in January 2027, adding capacity for active pharmaceutical ingredients.
“We see innovation becoming more global. We want to follow the customer. We want to have the critical infrastructure and capacities located where the customers are and give them more flexible options,” Dr. Yang said.
Dr. Yang also highlighted Europe’s strong academic research base. WuXi AppTec aims to help researchers advance promising findings toward clinical development and commercialization, and to support early-stage European biotechs preparing to enter international markets.
The purpose of these investments is to give customers access to the capabilities and capacity they need as their programs progress.
Discussing what biopharma collaboration could look like in 2030, Dr. Yang described a one-person startup using large language models and working with several drug research and development partners, including WuXi AppTec, to advance its work.
The example illustrates how a small team can draw on expertise and resources beyond its own organization. Tools such as large language models may help more individuals and small companies pursue scientific ideas, while specialized partners provide research, development, and manufacturing support.
This points to new models for biopharma collaboration: more diverse innovators, more specialized capabilities, and more open partner networks. Scientific resources, technical strengths, and industry experience from different regions can be effectively connected through global cooperation. Innovators can focus more intensively on the science itself, while relying on professional partners to speed translation of their discoveries.
As scientific ideas emerge from teams of varied sizes and locations, partners will need to understand what each program requires and prepare to support its next stage. That is the practical role Dr. Yang described for WuXi AppTec: helping customers advance their science through the capabilities and execution their programs need.
When collaboration is grounded in trust, and when capabilities are built ahead of demand, the industry can navigate uncertainty more effectively. When that happens, scientific concepts can turn into reality faster and innovations can reach patients more quickly. This is, ultimately, the benefit that collaboration delivers.